Autoimmune hemolytic anemia, cold type

Summary

Autoimmune hemolytic anemia, cold type (MONDO:0016450) is a disease. A subtype of autoimmune hemolytic anemia — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Prevalence: 1-9 / 100 000 (Europe)

Clinical features

Epidemiology

Prevalence records

1 prevalence record(s), Orphanet:

Type	Class	Value	Geography	Validation
Point prevalence	1-9 / 100 000		Europe	Not yet validated

Identifiers

Disease identifiers

Field	Value
Canonical name	autoimmune hemolytic anemia, cold type
Mondo ID	MONDO:0016450
Orphanet	228312
ICD-11	1836938544
UMLS	C0175816
MedGen	104501
GARD	0020590
Is cancer (heuristic)	no

Also known as: cAHA · cAIHA · cold AIHA

Disease family

This is a subtype of autoimmune hemolytic anemia. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › hematologic disorder › autoimmune disorder of blood › autoimmune hemolytic anemia › autoimmune hemolytic anemia, cold type

Related subtypes (6): Evans syndrome, neonatal autoimmune hemolytic anemia, autoimmune hemolytic anemia, warm type, mixed-type autoimmune hemolytic anemia, drug-induced autoimmune hemolytic anemia, giant cell hepatitis with autoimmune hemolytic anemia

Subtypes (2): cold agglutinin disease, paroxysmal cold hemoglobinuria

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.